Myelofibrosis

Hematology·MeSH: Primary Myelofibrosis

Prevalence

5.0 / 100K

40 drugs in development·22 companies·32 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
vonjo	CTI BIOPHARMA CORP (CTIC)

Phase 3(14)

Drug	Company
best available therapy	GERON CORP (GERN)
elritercept	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
elritercept	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
elritercept	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
elritercept (KER-050)	Keros Therapeutics, Inc. (KROS)
fedratinib	BRISTOL MYERS SQUIBB CO (BMY)
itacitinib	Incyte Corp. (INCY)
JAK Inhibitor	Assertio Holdings, Inc. (ASRT)
luspatercept	CELGENE CORP /DE/ (CELG)
momelotinib	Sierra Oncology, Inc. (SRRA)
navitoclax	AbbVie Inc. (ABBV)
parsaclisib	Incyte Corp. (INCY)
pelabresib	Novartis AG (NVS)
pelabresib	Novartis AG (NVS)

Phase 2(13)

Drug	Company
bomedemstat	UNITED THERAPEUTICS Corp (UTHR)
Busulfan	Assertio Holdings, Inc. (ASRT)
cpi-0610	CONSTELLATION PHARMACEUTICALS INC (CNST)
Fludarabine	Assertio Holdings, Inc. (ASRT)
gb2064	Damora Therapeutics, Inc. (DMRA)
hydroxycarbamide	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
imetelstat	GERON CORP (GERN)
incb057643	Incyte Corp. (INCY)
Melphalan	Assertio Holdings, Inc. (ASRT)
momelotinib	Karyopharm Therapeutics Inc. (KPTI)
pacritinib	Karyopharm Therapeutics Inc. (KPTI)
Tacrolimus	ENANTA PHARMACEUTICALS INC (ENTA)
Tacrolimus	Assertio Holdings, Inc. (ASRT)

Phase 1(4)

Drug	Company
bkm120	Novartis AG (NVS)
disc-0974	Disc Medicine, Inc. (IRON)
inc424	Novartis AG (NVS)
pelabresib	CONSTELLATION PHARMACEUTICALS INC (CNST)

Preclinical(3)

Drug	Company
dmr-001	Damora Therapeutics, Inc. (DMRA)
JAK2 program	Cogent Biosciences, Inc. (COGT)
morf-088	Morphic Holding, Inc. (MORF)

BLA Filed(1)

Drug	Company
fedratinib	CELGENE CORP /DE/ (CELG)

Phase 4(4)

BioSniper tracks 40 drugs in development for Myelofibrosis across 22 companies.

There are 32 clinical trials targeting Myelofibrosis tracked by BioSniper.

The estimated prevalence of Myelofibrosis is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.